Vigil Neuroscience announces first patient dosed in Phase 1 trial of VG-3927

Vigil Neuroscience announced that the Company has dosed its first participant in a Phase 1 clinical trial in healthy volunteers evaluating VG-3927, the first and only small molecule TREM2 agonist in the clinic for the potential treatment of Alzheimer’s disease, AD. “Dosing the first participant in our Phase 1 trial of VG-3927, the first and only small molecule TREM2 agonist in clinical development for assessment in AD, is an important milestone in our multi-modality strategy to develop novel therapeutics for the treatment of rare and common neurodegenerative diseases,” said Ivana Magovevi-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. “With approximately 6.7 million Americans living with AD, there remains a significant need for new therapies with improved safety and efficacy and that can broadly address multiple aspects of AD disease pathophysiology. Our orally bioavailable and highly CNS penetrant TREM2 agonist VG-3927 has a differentiated mechanism of action with multiple potential therapeutic advantages in AD, and we are excited to advance VG-3927 to potentially bring a differentiated treatment option to AD patients.” The double-blind, placebo-controlled Phase 1 clinical trial plans to evaluate VG-3927 in SAD and MAD ascending dose cohorts in healthy volunteers. The study is designed to evaluate VG-3927’s safety and tolerability, pharmacokinetics, and pharmacodynamics. The Company anticipates reporting interim Phase 1 topline data in mid-2024